{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:32:02Z","timestamp":1787059922994,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":18,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/02093"],"award-info":[{"award-number":["PI24\/02093"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["16\/11\/0432"],"award-info":[{"award-number":["16\/11\/0432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["16\/11\/00420"],"award-info":[{"award-number":["16\/11\/00420"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["16\/11\/00403"],"award-info":[{"award-number":["16\/11\/00403"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Regional Development Fund\/European Social Fund"},{"DOI":"10.13039\/100008055","name":"Fundacion Eugenio Rodriguez Pascual","doi-asserted-by":"publisher","award":["FERP-2023-0019"],"award-info":[{"award-number":["FERP-2023-0019"]}],"id":[{"id":"10.13039\/100008055","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["89013865"],"award-info":[{"award-number":["89013865"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"MCIN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pro-CNIC Foundation"},{"name":"Severo Ochoa Centers of Excellence programme","award":["CEX2020-001041-S"],"award-info":[{"award-number":["CEX2020-001041-S"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Recognition of transthyretin cardiac amyloidosis (ATTR-CA) remains challenging. In heart failure, plasmatic carbohydrate antigen 125 (CA125) is an established biomarker, reflecting inflammation and volume overload, common issues in ATTR-CA. Our aim was to evaluate the potential utility of CA125 as a \u2018rule-in\u2019 biomarker for suspected ATTR-CA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>This is a retrospective, multicentre, case\u2013control study that included 626 consecutive ambulatory patients (median age 79 years, 74.8% male) from three tertiary centres. All individuals underwent 99mTc-DPD scintigraphy for suspected cardiac amyloidosis and had a CA125 determination available at the time of the evaluation. Following diagnostic workup, 451 (72%) patients were diagnosed with ATTR-CA, while 175 (28%) were ruled out for the disease. Patients with ATTR-CA showed a non-significant trend towards higher CA125 levels (16.2 [10.2\u201329.7] vs 14 [8\u201326.3] U\/mL, P = .065). A CA125 cut-off of 40\u2005U\/mL yielded a positive predictive value of 81.7% (95% confidence interval: 78.6%\u201384.7%). In a multivariate logistic regression model, CA125 was an independent predictor for the diagnosis of ATTR-CA (odds ratio 2.109; 95% confidence interval: 1.197\u20133.717; P = .01). Combining CA125 (&amp;gt;40\u2005U\/mL) and N-terminal pro B-type natriuretic peptide (NT-proBNP) (&amp;gt;2500\u2005pg\/mL) significantly improved the diagnostic accuracy of the model. Patients with both biomarkers above their respective cut-offs had a three-fold higher likelihood of ATTR-CA (odds ratio: 3.38; 1.704\u20136.719; P &amp;lt; .001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In ambulatory patients with suspected ATTR-CA, a CA125 &amp;gt; 40\u2005U\/mL, particularly when combined with elevated NT-proBNP, supports the clinical suspicion of the disease. High CA125 levels may be useful in ATTR-CA recognition.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag199","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:22:16Z","timestamp":1784546536000},"source":"Crossref","is-referenced-by-count":0,"title":["High CA125 levels as a red flag for ATTR cardiac amyloidosis"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9081-7003","authenticated-orcid":false,"given":"Bel\u00e9n","family":"Peir\u00f3-Avent\u00edn","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , 28222 Majadahonda ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , 28029 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Santas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario de Valencia, INCLIVA , 46010 Valencia ,","place":["Spain"]},{"name":"Universitat de Valencia , 46010 Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Ruiz-Cueto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitari Germans Trias i Pujol , 08916 Badalona ,","place":["Spain"]},{"name":"Departamento de Medicina, Universidad Aut\u00f3noma de Barcelona , 08193 Barcelona ,","place":["Spain"]},{"name":"CIBER Cardiovascular , 28029 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Mora-Ayestar\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , 28222 Majadahonda ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , 28029 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Brice\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , 28222 Majadahonda ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Badia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitari Germans Trias i Pujol , 08916 Badalona ,","place":["Spain"]},{"name":"Departamento de Medicina, Universidad Aut\u00f3noma de Barcelona , 08193 Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"de Castro","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , 28222 Majadahonda ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , 28029 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8720-3999","authenticated-orcid":false,"given":"Rafael","family":"de la Espriella","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario de Valencia, INCLIVA , 46010 Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basilio","family":"Angulo-Lara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , 28222 Majadahonda ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Espinoza","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , 28222 Majadahonda ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge De La Fuente","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , 28222 Majadahonda ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel Maeztu","family":"Rada","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Basurto , 48013 Bilbao ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi Segarra","family":"Vidal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital General de Castell\u00f3n , 12004 Castell\u00f3n ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Dom\u00ednguez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , 28222 Majadahonda ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , 28029 Madrid ,","place":["Spain"]},{"name":"CIBER Cardiovascular , 28029 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Gonz\u00e1lez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , 28222 Majadahonda ,","place":["Spain"]},{"name":"CIBER Cardiovascular , 28029 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Bay\u00e9s-Gen\u00eds","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitari Germans Trias i Pujol , 08916 Badalona ,","place":["Spain"]},{"name":"Departamento de Medicina, Universidad Aut\u00f3noma de Barcelona , 08193 Barcelona ,","place":["Spain"]},{"name":"CIBER Cardiovascular , 28029 Madrid ,","place":["Spain"]},{"name":"ICREC Research Program, Instituto de Investigaci\u00f3n Germans Trias i Pujol (IGTP) , Badalona, 08916 Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Garcia-Pavia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , 28222 Majadahonda ,","place":["Spain"]},{"name":"Centro Nacional de Investigaciones Cardiovasculares (CNIC) , 28029 Madrid ,","place":["Spain"]},{"name":"CIBER Cardiovascular , 28029 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1672-7119","authenticated-orcid":false,"given":"Julio","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario de Valencia, INCLIVA , 46010 Valencia ,","place":["Spain"]},{"name":"Universitat de Valencia , 46010 Valencia ,","place":["Spain"]},{"name":"CIBER Cardiovascular , 28029 Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"2026081809215911000_xvag199-B1","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial diseases","volume":"42","author":"Garc\u00eda-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026081809215911000_xvag199-B2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.rec.2024.07.005","article-title":"Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study","volume":"78","author":"Garc\u00eda-Pav\u00eda","year":"2025","journal-title":"Rev Esp Cardiol"},{"key":"2026081809215911000_xvag199-B3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/ehjcvp\/pvae044","article-title":"Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review","volume":"10","author":"Rehman","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026081809215911000_xvag199-B4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2026081809215911000_xvag199-B5","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/ejhf.2295","article-title":"Antigen carbohydrate 125 as a biomarker in heart failure. A narrative review","volume":"23","author":"N\u00fa\u00f1ez","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026081809215911000_xvag199-B6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jchf.2019.12.005","article-title":"Clinical role of CA125 in worsening heart failure. A BIOSTAT-CHF study subanalysis","volume":"8","author":"N\u00fa\u00f1ez","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026081809215911000_xvag199-B7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jacc.2023.05.011","article-title":"Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure","volume":"82","author":"Docherty","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026081809215911000_xvag199-B8","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/ejhf.3166","article-title":"Carbohydrate antigen 125 concentrations across the ejection fraction spectrum in chronic heart failure: the EMPEROR programme","volume":"26","author":"Ferreira","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026081809215911000_xvag199-B9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1186\/s12967-024-05351-z","article-title":"Carbohydrate antigen 125 on epicardial fat and its association with local inflammation and fibrosis-related markers","volume":"22","author":"Eiras","year":"2024","journal-title":"J Transl Med"},{"key":"2026081809215911000_xvag199-B10","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1038\/s41598-024-84622-7","article-title":"The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burden","volume":"15","author":"Revuelta-L\u00f3pez","year":"2025","journal-title":"Sci Rep"},{"key":"2026081809215911000_xvag199-B11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012146","article-title":"Myocardial inflammation in cardiac transthyretin amyloidosis: prevalence and potential prognostic implications","volume":"18","author":"Muller","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026081809215911000_xvag199-B12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026081809215911000_xvag199-B13","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jchf.2020.03.007","article-title":"Utility of biomarkers in cardiac amyloidosis","volume":"8","author":"Pregenzer-Wenzler","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026081809215911000_xvag199-B14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/ejhf.2769","article-title":"N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis","volume":"25","author":"Vergaro","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026081809215911000_xvag199-B15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaccao.2024.10.013","article-title":"Biomarkers to predict abnormal technetium-99m pyrophosphate scans in patients with suspected transthyretin amyloidosis","volume":"7","author":"De Michieli","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026081809215911000_xvag199-B16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ijcard.2020.03.027","article-title":"CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation","volume":"308","author":"Soler","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026081809215911000_xvag199-B17","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1177\/2048872620908033","article-title":"Factors associated with plasma antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide concentrations in acute heart failure","volume":"9","author":"Mi\u00f1ana","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026081809215911000_xvag199-B18","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1007\/s00392-024-02512-4","article-title":"Incremental prognostic utility of congestion markers in cardiac transthyretin amyloidosis","volume":"115","author":"Ihne-Schubert","year":"2026","journal-title":"Clin Res Cardiol"},{"key":"2026081809215911000_xvag199-B19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.122.010078","article-title":"Hemodynamic profiling and prognosis in cardiac amyloidosis","volume":"16","author":"Martens","year":"2023","journal-title":"Circ Heart Fail"},{"key":"2026081809215911000_xvag199-B20","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.692083","article-title":"High serum carbohydrate antigen (CA) 125 level is associated with poor prognosis in patients with light-chain cardiac amyloidosis","volume":"8","author":"Li","year":"2021","journal-title":"Front Cardiovasc Med"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag199\/69728653\/xvag199.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/4\/xvag199\/69728653\/xvag199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/4\/xvag199\/69728653\/xvag199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:22:03Z","timestamp":1787059323000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag199\/8739485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7,22]]},"published-print":{"date-parts":[[2026,7,4]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag199","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,4]]},"article-number":"xvag199"}}